- Home
- HIVE vs PACB Comparison
HIVE vs PACB Comparison
Compare HIVE & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIVE
- PACB
- Stock Information
- Founded
- HIVE 1987
- PACB 2000
- Country
- HIVE United States
- PACB United States
- Employees
- HIVE N/A
- PACB N/A
- Industry
- HIVE
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- HIVE
- PACB Industrials
- Exchange
- HIVE Nasdaq
- PACB Nasdaq
- Market Cap
- HIVE 360.2M
- PACB 364.2M
- IPO Year
- HIVE N/A
- PACB 2010
- Fundamental
- Price
- HIVE $2.30
- PACB $1.47
- Analyst Decision
- HIVE Strong Buy
- PACB Buy
- Analyst Count
- HIVE 7
- PACB 9
- Target Price
- HIVE $6.57
- PACB $2.06
- AVG Volume (30 Days)
- HIVE 24.0M
- PACB 9.8M
- Earning Date
- HIVE 08-11-2025
- PACB 08-06-2025
- Dividend Yield
- HIVE N/A
- PACB N/A
- EPS Growth
- HIVE N/A
- PACB N/A
- EPS
- HIVE N/A
- PACB N/A
- Revenue
- HIVE $115,279,000.00
- PACB $152,357,000.00
- Revenue This Year
- HIVE $167.38
- PACB $3.33
- Revenue Next Year
- HIVE $68.08
- PACB $18.52
- P/E Ratio
- HIVE N/A
- PACB N/A
- Revenue Growth
- HIVE 0.71
- PACB N/A
- 52 Week Low
- HIVE $1.26
- PACB $0.85
- 52 Week High
- HIVE $5.54
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- HIVE 66.14
- PACB 60.56
- Support Level
- HIVE $2.09
- PACB $1.41
- Resistance Level
- HIVE $2.44
- PACB $1.53
- Average True Range (ATR)
- HIVE 0.18
- PACB 0.10
- MACD
- HIVE 0.04
- PACB 0.01
- Stochastic Oscillator
- HIVE 80.46
- PACB 66.00
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.